Antibody collaboration deal for Scancell CEO Cliff Holloway tells Proactive London why its antibody collaboration deal is significant and details how it complements Scancell's existing antibody technology. He also explains what is unique about Scancell's antibody pipeline.
Scancell signs first collaboration agreement for its new platform technology, AvidiMab™ To download click here
Scancell hails first antibody collaboration deal The company is teaming up with an unnamed "major player" in the world of antibodies. [View Article]
Scancell at the frontier of cancer therapy The Shares magazine August 2019 Spotlight profile of Scancell. Click here to view.